Dimensional Fund Advisors LP grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 173,257 shares of the company’s stock after acquiring an additional 6,149 shares during the period. Dimensional Fund Advisors LP owned about 0.19% of Neurocrine Biosciences worth $12,369,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in NBIX. SG Americas Securities LLC increased its stake in Neurocrine Biosciences by 8.7% during the 4th quarter. SG Americas Securities LLC now owns 1,971 shares of the company’s stock worth $141,000 after buying an additional 157 shares during the period. Sumitomo Life Insurance Co. increased its position in shares of Neurocrine Biosciences by 1.8% in the 4th quarter. Sumitomo Life Insurance Co. now owns 9,939 shares of the company’s stock valued at $710,000 after purchasing an additional 180 shares during the last quarter. Rehmann Capital Advisory Group increased its position in shares of Neurocrine Biosciences by 54.7% in the 3rd quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock valued at $68,000 after purchasing an additional 197 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Neurocrine Biosciences by 7.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,116 shares of the company’s stock valued at $437,000 after purchasing an additional 448 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $32,000.
A number of brokerages have commented on NBIX. Zacks Investment Research raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating and set a $105.00 price objective on the stock in a research report on Wednesday, April 10th. Evercore ISI began coverage on shares of Neurocrine Biosciences in a report on Thursday, April 11th. They issued an “outperform” rating for the company. ValuEngine cut shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Friday, February 22nd. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Neurocrine Biosciences in a report on Wednesday, February 6th. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $103.48.
Shares of NASDAQ:NBIX opened at $78.43 on Friday. The firm has a market cap of $7.12 billion, a P/E ratio of 356.50, a price-to-earnings-growth ratio of 27.34 and a beta of 1.87. The company has a quick ratio of 8.24, a current ratio of 8.36 and a debt-to-equity ratio of 0.81. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.05. The firm had revenue of $131.49 million during the quarter, compared to analysts’ expectations of $132.32 million. Neurocrine Biosciences had a net margin of 4.68% and a return on equity of 5.06%. Neurocrine Biosciences’s quarterly revenue was up 39.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.07 EPS. As a group, research analysts expect that Neurocrine Biosciences, Inc. will post -0.04 earnings per share for the current fiscal year.
In other Neurocrine Biosciences news, insider Kyle Gano sold 3,809 shares of the company’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.12, for a total transaction of $335,649.08. Following the completion of the transaction, the insider now owns 17,595 shares in the company, valued at approximately $1,550,471.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin Charles Gorman sold 7,614 shares of the company’s stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $88.16, for a total transaction of $671,250.24. Following the transaction, the chief executive officer now owns 408,082 shares of the company’s stock, valued at approximately $35,976,509.12. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
See Also: Coverage Ratio
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.